Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Patterns of Total Costs of Care for Newly Diagnosed Multiple Myeloma (MM) Patients

Steven R. Arikian, Dejan Milentijevic, Gary Binder, Mara Silvia Monzini, X Henry Hu, Yasir Nagarwala, Mohamad A. Hussein, MD, Frank A. Corvino, Andy Surinach, Saad Z. Usmani, MD

Blood (2014) 124 (21): 2656.

https://doi.org/10.1182/blood.V124.21.2656.2656

Published: 2014

Journal Articles

Impact of Novel Treatments on Multiple Myeloma Survival

David Robinson, Satyin Kaura, MSci, MBA, Daniel Kiely, Mohamad A. Hussein, MD, Knar Nersesyan, Brian G. M. Durie, MD

Blood (2014) 124 (21): 5676.

https://doi.org/10.1182/blood.V124.21.5676.5676

Published: 2014

Journal Articles

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Rachid Baz, MD, Mohamad A Hussein, MD, Daniel Sullivan, MD, Jose-Leonel Ochoa-Bayona, M.D., Monique A Hartley, MD, Kenneth Shain, MD, PhD, Taiga Nishihori, MD, Jennifer Paleveda, Kara Kosakowski, William S. Dalton, PhD, MD, Melissa Alsina, MD

Blood (2010) 116 (21): 3054.

https://doi.org/10.1182/blood.V116.21.3054.3054

Published: 2010

Journal Articles

Balloon Kyphoplasty Improves Both Roland-Morris Disability Scores and Bone Pain among Cancer Patients with Vertebral Compression Fractures: Interim Analysis of Results from a Phase IV Random Trial

James R. Berenson, MD, John B Tillman, PhD, Mohamad A. Hussein, MD, Robert Pflugmacher, MD, Peter Jarzem, MD, Sami Elmoufti, MS, Frank D Vrionis, MD

Blood (2008) 112 (11): 3695.

https://doi.org/10.1182/blood.V112.11.3695.3695

Published: 2008

Journal Articles

Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.

Mohamad A. Hussein, MD, James R. Berenson, MD, Ruben Niesvizky, MD, Nikhil C. Munshi, MD, Jeffrey Matous, MD, Kate Harrop, BA, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 3576.

https://doi.org/10.1182/blood.V108.11.3576.3576

Published: 2006

Journal Articles

S0204: Melphalan (MEL)-Based Tandem Autotransplants (TAT) for Multiple Myeloma (MM) with Thalidomide/Dexamethasone (TD) Induction and Thalidomide/Prednisone (TP) Maintenance: A Phase II Trial of the Southwest Oncology Group.

Mohamad A. Hussein, MD, Andrzej J. Jakubowiak, MD, PhD, Vanessa Bolejack, MPH, Jeff Zonder, MD, John Crowley, PhD, Bart Barlogie

Blood (2006) 108 (11): 3088.

https://doi.org/10.1182/blood.V108.11.3088.3088

Published: 2006

Journal Articles

A Phase I Humanized Anti-CD40 Monoclonal Antibody (SGN-40) in Patients with Multiple Myeloma.

Mohamad A. Hussein, MD, James R. Berenson, MD, Ruben Niesvizky, MD, Nikhil C. Munshi, MD, Kate L. Harrop, Michael McDonald, MRCP, Jonathan G. Drachman, MD

Blood (2005) 106 (11): 2572.

https://doi.org/10.1182/blood.V106.11.2572.2572

Published: 2005

Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) Results in a High Response Rate in Patients with Refractory Multiple Myeloma (RMM).

Rachid Baz, MD, Toni K. Choueiri, MD, Rony Abou Jawde, MD, Bridget McGowan, Yvette Ellis, Catherine Brand, Mohamad A. Hussein, MD

Blood (2005) 106 (11): 2559.

https://doi.org/10.1182/blood.V106.11.2559.2559

Published: 2005

Journal Articles

SWOG 0204; Phase 2 Trial of Thalidomide (T) + Dexamethasone (D) Induction Followed by Tandem Autotransplant (TAT) and Prednisone (P) + T Maintenance for Multiple Myeloma (MM).

Mohamad A. Hussein, MD, Jason McCoy, MS, Andrzej Jakubowiak, MD, PhD, Brian G. Durie, MD, John J. Crowley, MD, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 1169.

https://doi.org/10.1182/blood.V106.11.1169.1169

Published: 2005

Journal Articles

Cyclin D1 Immunohistochemistry Identifies a Subset of Plasma Cell Myeloma with Superior Overall Survival.

James R. Cook, MD, PhD, Eric D. Hsi, MD, Raymond R. Tubbs, DO, Sarah Worley, Mohamad A. Hussein, MD

Blood (2004) 104 (11): 4854.

https://doi.org/10.1182/blood.V104.11.4854.4854

Published: 2004

Journal Articles

A Phase I, Multi-Dose, Dose Escalation Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma.

Mohamad A. Hussein, MD, Ruben Niesvizky, MD, Nikhil Munshi, MD, James C. Berenson, MD, Kenneth C. Anderson, MD, Kate Ryan, BA, Karen Baumgartner, BA, Dennis M. Miller, PhD, Michael McDonald, MD

Blood (2004) 104 (11): 2413.

https://doi.org/10.1182/blood.V104.11.2413.2413

Published: 2004

Journal Articles

Arsenic Trioxide (Trisenox® ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report.

Rony M. Abou-Jawde, MD, Janice Reed, RN, Megan Kelly, Luba Platt, BS, Mary Ann Karam, RN, Mary Ruth Kovak, MSN, MBA, Gordan Srkalovic, MD, PhD, Mohamad A. Hussein, MD

Blood (2004) 104 (11): 2419.

https://doi.org/10.1182/blood.V104.11.2419.2419

Published: 2004

Journal Articles

Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.

Ian W. Flinn, MD, PhD, Elizabeth Kumm, MS, Michael R. Grever, MD, Donna Neuberg, ScD, Gordon W. Dewald, PhD, John M. Bennett, MD, Elisabeth M. Paietta, PhD, Mohamad A. Hussein, MD, Dennis F. Moore, Jr., MD, Martin S. Tallman, MD

Blood (2004) 104 (11): 475.

https://doi.org/10.1182/blood.V104.11.475.475

Published: 2004

Journal Articles

Bisphosphonate Therapy Associated with an Increased Incidence of Mandibular/Maxillary Osteomyelitis in Multiple Myeloma Patients.

Snehal G. Thakkar, MD, Carlos Isada, MD, Kristin Englund, MD, Walter Tomford, MD, Mary Ann Karam, RN, Janice L. Reed, RN, James Smith, DDS, Mohamad A. Hussein, MD

Blood (2004) 104 (11): 4925.

https://doi.org/10.1182/blood.V104.11.4925.4925

Published: 2004

Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Mohamad A. Hussein, MD, Mary Ann Karam, RN, Catherine Brand, Greg L. Pearce, Janice Reed, RN, Kellie Bruening, Paul Sartori, Gordan Srkalovic, MD, PhD, Marta Olesnyckyj, RN, Robert Knight, MD, Kathe Balinski, RN, MA, Jerome Zeldis, MD, PhD

Blood (2004) 104 (11): 208.

https://doi.org/10.1182/blood.V104.11.208.208

Published: 2004

NARROW

Patterns of Total Costs of Care for Newly Diagnosed Multiple Myeloma (MM) Patients

Impact of Novel Treatments on Multiple Myeloma Survival

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Balloon Kyphoplasty Improves Both Roland-Morris Disability Scores and Bone Pain among Cancer Patients with Vertebral Compression Fractures: Interim Analysis of Results from a Phase IV Random Trial

Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.

S0204: Melphalan (MEL)-Based Tandem Autotransplants (TAT) for Multiple Myeloma (MM) with Thalidomide/Dexamethasone (TD) Induction and Thalidomide/Prednisone (TP) Maintenance: A Phase II Trial of the Southwest Oncology Group.

A Phase I Humanized Anti-CD40 Monoclonal Antibody (SGN-40) in Patients with Multiple Myeloma.

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) Results in a High Response Rate in Patients with Refractory Multiple Myeloma (RMM).

SWOG 0204; Phase 2 Trial of Thalidomide (T) + Dexamethasone (D) Induction Followed by Tandem Autotransplant (TAT) and Prednisone (P) + T Maintenance for Multiple Myeloma (MM).

Cyclin D1 Immunohistochemistry Identifies a Subset of Plasma Cell Myeloma with Superior Overall Survival.

A Phase I, Multi-Dose, Dose Escalation Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma.

Arsenic Trioxide (Trisenox® ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report.

Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.

Bisphosphonate Therapy Associated with an Increased Incidence of Mandibular/Maxillary Osteomyelitis in Multiple Myeloma Patients.

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only